186 related articles for article (PubMed ID: 34339030)
1. Pharmacological Effects of Natural Components Against Ovarian Cancer and Mechanisms.
Liu H; Liu SL
Adv Exp Med Biol; 2021; 1330():55-73. PubMed ID: 34339030
[TBL] [Abstract][Full Text] [Related]
2. Enterolactone has stronger effects than enterodiol on ovarian cancer.
Liu H; Liu J; Wang S; Zeng Z; Li T; Liu Y; Mastriani E; Li QH; Bao HX; Zhou YJ; Wang X; Hu S; Gao S; Qi Y; Shen Z; Wang H; Yu M; Gao T; Johnston RN; Liu SL
J Ovarian Res; 2017 Jul; 10(1):49. PubMed ID: 28738876
[TBL] [Abstract][Full Text] [Related]
3. Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9.
Liu H; Zeng Z; Wang S; Li T; Mastriani E; Li QH; Bao HX; Zhou YJ; Wang X; Liu Y; Liu W; Hu S; Gao S; Yu M; Qi Y; Shen Z; Wang H; Gao T; Dong L; Johnston RN; Liu SL
Cancer Biol Ther; 2017 Dec; 18(12):990-999. PubMed ID: 29173024
[TBL] [Abstract][Full Text] [Related]
4. Suppressive activities of mangiferin on human epithelial ovarian cancer.
Zeng Z; Lin C; Wang S; Wang P; Xu W; Ma W; Wang J; Xiang Q; Liu Y; Yang J; Ye F; Xie K; Xu J; Luo Y; Liu SL; Liu H
Phytomedicine; 2020 Jun; 76():153267. PubMed ID: 32570111
[TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
6. Acanthopanax senticosus: Photochemistry and Anticancer Potential.
Li T; Ferns K; Yan ZQ; Yin SY; Kou JJ; Li D; Zeng Z; Yin L; Wang X; Bao HX; Zhou YJ; Li QH; Zhao ZY; Liu H; Liu SL
Am J Chin Med; 2016; 44(8):1543-1558. PubMed ID: 27852123
[TBL] [Abstract][Full Text] [Related]
7. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
Chen SS; Michael A; Butler-Manuel SA
Discov Med; 2012 Jan; 13(68):7-17. PubMed ID: 22284780
[TBL] [Abstract][Full Text] [Related]
11. Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer.
Altman AD; Lambert P; Dean E; Robinson C; Nachtigal MW; Kean S
J Obstet Gynaecol Can; 2020 Oct; 42(10):1217-1222. PubMed ID: 32694071
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
14. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.
Drisko JA; Chapman J; Hunter VJ
J Am Coll Nutr; 2003 Apr; 22(2):118-23. PubMed ID: 12672707
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
[No Abstract] [Full Text] [Related]
16. Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Bandera EV; Lee VS; Rodriguez-Rodriguez L; Powell CB; Kushi LH
JAMA Oncol; 2015 Sep; 1(6):737-45. PubMed ID: 26181758
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
18. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
19. Anticancer and antimetastatic potential of enterolactone: Clinical, preclinical and mechanistic perspectives.
Mali AV; Padhye SB; Anant S; Hegde MV; Kadam SS
Eur J Pharmacol; 2019 Jun; 852():107-124. PubMed ID: 30771348
[TBL] [Abstract][Full Text] [Related]
20. In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers.
Patel NR; Piroyan A; Ganta S; Morse AB; Candiloro KM; Solon AL; Nack AH; Galati CA; Bora C; Maglaty MA; O'Brien SW; Litwin S; Davis B; Connolly DC; Coleman TP
Cancer Biol Ther; 2018 Jul; 19(7):554-564. PubMed ID: 29737910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
